Dempsey Amanda F
University of Colorado Denver, 13199 East Montview Blvd, Suite 300, Aurora, CO, 80045, USA.
Isr J Health Policy Res. 2017 Oct 13;6(1):56. doi: 10.1186/s13584-017-0181-0.
Human papillomavirus (HPV) vaccination holds great promise for drastically reducing the incidence of HPV-associated cancers of the genital tract, and possibly also certain head and neck cancers. Unfortunately, rates of HPV vaccine utilization among adolescents are low in many countries. Many research studies have identified the fact that HPV is a sexually transmitted infection as a barrier to higher vaccination rates. This is related to providers' and parents' reluctance to discuss or consider the burgeoning sexuality of their child. An approach suggested to overcome this barrier is to "desexualize" the vaccine. This entails focusing discussions and public messages on the cancer-preventing properties of the vaccine and ignoring or minimizing information about HPV's sexual transmissibility. In an article by Velan and Yadgar, the authors argue that this approach does more harm than good. This associated commentary offers a slightly different viewpoint from one who has been "in the trenches" both clinically and from a research standpoint for many years.
人乳头瘤病毒(HPV)疫苗接种有望大幅降低与HPV相关的生殖道癌症以及可能的某些头颈癌的发病率。不幸的是,许多国家青少年中HPV疫苗的接种率很低。许多研究已确定,HPV是一种性传播感染这一事实是提高接种率的障碍。这与医护人员和家长不愿讨论或考虑其子女日益萌动的性特征有关。为克服这一障碍而建议的一种方法是使疫苗“去性化”。这需要将讨论和公共信息聚焦于疫苗的防癌特性,并忽略或尽量减少有关HPV性传播的信息。在韦兰和亚德加的一篇文章中,作者认为这种方法弊大于利。这篇相关评论提供了一个与多年来一直身处临床和研究一线的人略有不同的观点。